Surface Oncology, Inc. financial data

Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2023 - 02 Aug 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 679 % -22.5%
Debt-to-equity 64.4 % +25.5%
Return On Equity -112 % -1.3%
Return On Assets -67.95 % -1.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60,824,474 shares +4.8%
Common Stock, Shares, Outstanding 60,730,274 shares +9.7%
Common Stock, Value, Issued 6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 60,717,899 shares +11.1%
Weighted Average Number of Shares Outstanding, Diluted 60,717,899 shares +11.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 59,789,000 USD -8.3%
General and Administrative Expense 26,362,000 USD +1.3%
Operating Income (Loss) -89,385,000 USD -47.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -92,505,000 USD -46.9%
Earnings Per Share, Basic -2 USD/shares -24%
Earnings Per Share, Diluted -2 USD/shares -24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14,842,000 USD -80.2%
Assets, Current 60,588,000 USD -62.5%
Property, Plant and Equipment, Net 2,499,000 USD -51.9%
Operating Lease, Right-of-Use Asset 2,919,000 USD -88.5%
Other Assets, Noncurrent 0 USD -100%
Assets 66,006,000 USD -66%
Accounts Payable, Current 609,000 USD +25.3%
Liabilities, Current 16,828,000 USD -14.7%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 16,828,000 USD -75.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -221,000 USD +81.1%
Retained Earnings (Accumulated Deficit) -252,262,000 USD -57.9%
Stockholders' Equity Attributable to Parent 49,178,000 USD -60.9%
Liabilities and Equity 66,006,000 USD -66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23,439,000 USD +0.54%
Net Cash Provided by (Used in) Financing Activities 77,000 USD -99.6%
Net Cash Provided by (Used in) Investing Activities 1,434,000 USD -88.5%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 60,730,274 shares +9.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21,928,000 USD -3.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1,746,000 USD +2.3%
Payments to Acquire Property, Plant, and Equipment 17,000 USD -51.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -91,556,000 USD -42.8%
Operating Lease, Liability, Current 9,488,000 USD +65.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 318,000 USD -7.8%
Share-based Payment Arrangement, Expense 6,117,000 USD -21.8%
Interest Expense 5,771,000 USD +1.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%